CoChat

Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines

Quagliato, Laiana A., Freire, Rafael C., Nardi, Antonio E. · 2018 · Expert Opinion on Drug Safety

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Panic disorder (PD) is a prevalent and disabling anxiety disorder that can be treated effectively. Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines are among the most frequently prescribed drugs for PD. In this article, the authors review the current evidence on efficacy, adverse events, and limitations of these two treatment options. AREAS COVERED: MEDLINE/Pubmed and Web of Science databases were searched for open or placebo-controlled trials on SSRIs and/or benzodiazepines in PD treatment. EXPERT OPINION: The literature search yielded 4,957 articles related to the theme. Of these, 24 articles were included in this review. Despite their usefulness in PD, SSRIs are associated with a delay of several weeks in onset of therapeutic effect and have the potential to exacerbate anxiety and panic early in the treatment course. Benzodiazepines present rapid onset of action, but can cause tolerance and dependence. Despite strong evidence of the effectiveness of SSRIs and benzodiazepines in the treatment of PD, few trials have performed head-to-head comparisons of these two drug classes. Future studies on the pharmacological treatment of PD should make direct comparisons of risks, benefits, and limitations of each group. This could help improve the evidence-based pharmacotherapy of PD.

Overview

Integrity signals

Registry

Crossref · 10.1080/14740338.2018.1429403

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 72 references

Research works printed but not linked: 6

  1. Association WGOPDAP, 1998, Am J Psychiatry, 155, 1
  2. Black K., 2000, J Psychiatry Neurosci, 25, 255
  3. Nardi AE, 2013, Curr Drug Targets, 14, 353
  4. Longo LP, 2000, Am Fam Physician, 61, 2121
  5. Bighelli I, 2016, Cochrane Lib
  6. Liu B.A., 1996, Can Med Assoc J, 155, 519

Cited by

See all 62

Metadata

Authors
Quagliato, L. A., Freire, R. C., & Nardi, A. E.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Laboratory of Panic & Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Corresponding author
Quagliato, Laiana A.
Venue
Expert Opinion on Drug Safety
Published
2018-01-22
Volume
17
Issue
3
Pages
315-324
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W2794421769
Cited by
62
References
71
Citations by year
2026: 4 · 2025: 6 · 2024: 25 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 3
FWCI
4.91
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
panic disorder, selective serotonin reuptake inhibitors, benzodiazepines, pharmacotherapy, drug efficacy, adverse drug reactions, benzodiazepine dependence, tolerance (pharmacology and immunology), head-to-head comparison
MeSH terms
Benzodiazepines, Drug Tolerance, Humans, Time Factors, Panic Disorder, Selective Serotonin Reuptake Inhibitors, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. https://app.cochat.ai/papers/10.1080/14740338.2018.1429403
The paper
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018). Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2018.1429403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.